HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Cochran, B. G. Articles by Overholser, B. R. Search for Related Content PubMed PubMed Citation Articles by Cochran, B. G. Articles by Overholser, B. R.

BRIAN G. COCHRAN, PHARM.D., BCOP is Oncology Pharmacy Specialist, The Cancer Center at Ball Memorial Hospital, Muncie, IN; at the time this study was conducted he was Oncology Pharmacy Resident, Indiana University Cancer Center (IUCC), Indianapolis. KEVIN M. SOWINSKI, PHARM.D., BCPS, FCCP, is Associate Professor, Department of Pharmacy Practice, School of Pharmacy and Pharmaceutical Sciences, Purdue University (PU), West Lafayette, IN, and Adjunct Associate Professor, Department of Medicine, School of Medicine, Indiana University (IU), Indianapolis. CHRISTOPHER FAUSEL, PHARM. D., BCPS, BCOP, is Clinical Pharmacist, Hematology/Oncology/Bone Marrow Transplant, IUCC. BRIAN R. OVERHOLSER, PHARM.D., is Assistant Professor, Department of Pharmacy Practice, School of Pharmacy and Pharmaceutical Sciences, PU, and Adjunct Assistant Professor, Department of Medicine, School of Medicine, IU.

Address correspondence to Dr. Overholser at the Department of Pharmacy Practice, School of Pharmacy and Pharmaceutical Sciences, Purdue University, W7555 Myers Building, WHS, 1001 West 10th Street, Indianapolis, IN 46202 (boverhol{at}purdue.edu).

Purpose. The physical compatibility and chemical stability of mycophenolate mofetil during simulated Y-site administration with commonly coadministered drugs were studied. Methods. The physical compatibility and chemical stability of mycophenolate mofetil were tested with cefepime, cyclosporine, dopamine, norepinephrine, tacrolimus, vancomycin, and 0.9% sodium chloride injection. Physical compatibility of mycophenolate with the test drugs was assessed visually with the unaided eye. Mycophenolate concentrations in solution were determined by a high-performance liquid chromatographic method with ultraviolet-light detection. Test drugs were added to the mycophenolate solutions, and the mycophenolate concentrations were recorded as a percentage of the original concentration based on the mean of the three control and three test concentrations. Drug combinations were considered chemically unstable if the initial mycophenolate concentration changed by 10% at zero (baseline), one, two, or four hours. Results. The mycophenolate solution remained clear and colorless after the addition of all test drugs except cyclosporine. The combination of cyclosporine with mycophenolate resulted in an effervescence that remained after four hours. Cyclosporine was the only test drug that resulted in a mean percentage change that exceeded 10% (10.3% ± 2.3%) of the initial mycophenolate concentration. Conclusion. Mycophenolate mofetil was physically compatible and chemically stable with vancomycin, cefepime, norepinephrine, dopamine, and tacrolimus for up to four hours of simulated Y-site administration. The physical compatibility of mycophenolate mofetil with cyclosporine could not be confirmed. Index terms: Concentration; Cyclosporine; Effervescence; Immunosuppressive agents; Incompatibilities; Injections; Mycophenolate mofetil; Stability; Storage